China CDE has accepted the IND application for JS125/WJ47156 submitted by Junshi Bioscience. JS125/WJ47156, a novel HDAC1/2/3 inhibitor, is co-developed by Junshi and Wigen Biomedicine. In 2020, they announced the first collaboration agreement including 4 cancer drug candidates (XPO1 inhibitor, Aurora-A inhibitor, EGFR-exon20 inhibitor, and 4th generation EGFR inhibitor). In the 2022 interim financial results, Junshi disclosed that they had expanded their collaboration with Wigen to include four additional cancer drug candidates (IDH1 inhibitor, SHP2 inhibitor, FGFR2 inhibitor, and ATR inhibitor). JS125/WJ47156 may be part of the third collaboration (not disclosed so far) patch between Junshi and Wigen Biomedicine. JS125/WJ47156 JS125/WJ47156, a novel HDAC inhibitor, is co-developed by Junshi and Wigen Biomedicine as a cancer treatment. According to the press release , JS125/WJ47156 selectively inhibits HDAC1, HDAC2, and HDAC3, leading to cell ...
China Biotech XYZ Shares Updates Related to New Drug Development in China